Telemachus Therapeutics, Inc. is raising $1,500,000 through an exempt securities offering, with $125,000 already sold. Investors can see that $1,375,000 remains in the offering, while the instrument is structured as a Simple Agreement for Future Equity, identifying the funding terms and remaining availability.
Key Highlights
- The offering lists a minimum Investment of $50,000.
- Michael Bozik and Gregory Hebrank are named executive officers, directors and promoters.
- The Form D reports that $125,000 had been sold in the $1,500,000 exempt offering.
Telemachus Therapeutics, Inc. is offering $1,500,000 in an exempt securities offering, with $125,000 already sold. The notice lists $1,375,000 as the unsold portion. The securities are structured as a Simple Agreement for Future Equity, or SAFE.
SAFE Offering Sets $1.5M Target
The minimum investment accepted is $50,000, while one investor is recorded in the offering information. Michael Bozik is listed at the Pittsburgh address as an executive officer, director and promoter. Gregory Hebrank is identified in the same capacities at 166 Firestone Road, Greensburg, Pennsylvania 15,601. Hebrank signed the notice as secretary on Sep. 2, 2026. The offering information records $125,000 in securities sold against the $1,500,000 target, leaving $1,375,000 identified as the remaining amount. The filing includes an Aug. 20, 2026 date in its offering information and classifies the securities under a SAFE arrangement. Telemachus Therapeutics’ listed officers, directors and promoters include Bozik and Hebrank.



Please wait processing your request...